The Selexis SURE CHO-M Cell Line's genome and transcriptome was sequenced by 2011. We have applied our powerful internally developed bioinformatics tools to support the ongoing genomic analysis of both the parental CHO-M cell line and client production cell lines. As a result, we have an unparalleled understanding of our manufacturing lines, which supports detailed regulatory packages and ongoing parental cell line improvements internally.
The SURE CHO-M Cell Line is a proprietary, high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins, including monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy has been optimized, allowing for faster and more efficient scale-up to bioreactors for biologics development. Therapeutics generated that have been using Selexis SURE CHO-M cells are in both clinical trials and marketed products.
Selexis specifically developed the SURE CHO-M Cell Line technology to address the issue of protein expression bottlenecks, which are typically time-consuming, labor-intensive, and dependent on the gene of interest to be expressed.
The High-Performance SURE CHO-M Cell Line